Akki - the "primary endpoint" is pretty important don't you think?
Most of Sarepta's drugs have been passed on surrogate end points. There is still a massive question regards to their efficacy.
The FDA have defo set a precedent with their lenient assessment of Sarepta's efficacy results.
It does show how strong the parent lobby groups are - another reason why we need US based staff to be in the "inner circle", and I don't mean a US director. Perhaps Anthony needs to start working out of the US?
The monkey tox study is key - that will open up the door for serious dialogue with partners now the 9-month tox study is validated.
If we can get a number north of 30 enrollments at the half year report - the market will respond well imo.
.
Akki - the "primary endpoint" is pretty important don't you...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |